5.85
Immatics N V Borsa (IMTX) Ultime notizie
Immatics N.V. Shareholders Approve Key Resolutions at June 2025 AGM - TipRanks
These Numbers Reveal How Powerful Immatics N.V (NASDAQ: IMTX) Stock Is - Stocksregister
Learn to Evaluate (IMTX) using the Charts - news.stocktradersdaily.com
Cantor Fitzgerald Comments on Immatics FY2026 Earnings - Defense World
Two Sigma Investments LP Sells 36,345 Shares of Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) Shares Sold by Two Sigma Advisers LP - Defense World
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - Revista ADVFN
Immatics rises on data from early stage cell therapy trial - MSN
Millennium Management LLC Has $1.11 Million Holdings in Immatics (NASDAQ:IMTX) - Defense World
Immatics: Taking Off On A PRAME Rocketship - Seeking Alpha
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect? - Yahoo Finance
Immatics Announces Annual General Meeting for June 2025 - TipRanks
immatics n.v. announces upcoming annual general meeting By Investing.com - Investing.com South Africa
immatics n.v. announces upcoming annual general meeting - Investing.com
Immatics (IMTX) Soars After Positive Trial Results for Cell Ther - GuruFocus
Cantor Fitzgerald reiterates overweight rating on Immatics stock By Investing.com - Investing.com UK
Immatics Presents Promising IMA203 Data at ASCO 2025 - TipRanks
Form 6-K Immatics N.V. For: Jun 02 - StreetInsider
Northern Trust Corp Purchases 11,304 Shares of Immatics (NASDAQ:IMTX) - Defense World
Immatics (IMTX) Shares Promising Data from IMA203 Melanoma Trials | IMTX Stock News - GuruFocus
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 - GlobeNewswire
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO - GuruFocus
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | IMTX Stock News - GuruFocus
Immatics N.V. Reports Promising Long-Term Efficacy and Safety Data from Phase 1b Trial of IMA203 PRAME Cell Therapy in Metastatic Melanoma - Nasdaq
PRAME Cell Therapy Shows 56% Response Rate in Melanoma Patients at ASCO 2025 | IMTX Stock News - Stock Titan
Immatics (NASDAQ:IMTX) Receives $17.00 Average Price Target from Analysts - Defense World
Immatics N.V. (IMTX) Stock Analysis: Uncovering a 163% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Long Term Trading Analysis for (IMTX) - news.stocktradersdaily.com
Immatics (NASDAQ:IMTX) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft - Defense World
D. E. Shaw & Co. Inc. Has $176,000 Stake in Immatics (NASDAQ:IMTX) - Defense World
Deutsche Bank Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation - Nasdaq
Immatics (IMTX) Receives "Buy" Rating from Deutsche Bank | IMTX Stock News - GuruFocus
Deutsche Bank Initiates Coverage on Immatics With Buy Rating, $10 Price Target - marketscreener.com
Deutsche Bank Gives Immatics (IMTX) a Boost with Buy Rating and $10 Target | IMTX Stock News - GuruFocus
Deutsche Bank sets $10 target for Immatics stock on Buy rating - Investing.com UK
Immatics FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S - simplywall.st
The Manufacturers Life Insurance Company Sells 71,487 Shares of Immatics (NASDAQ:IMTX) - Defense World
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely - Yahoo Finance
Immatics: Q1 Earnings Snapshot - CT Insider
Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewswire
Immatics NV earnings missed by €0.07, revenue topped estimates - Investing.com South Africa
Immatics NV reports results for the quarter ended March 31Earnings Summary - TradingView
IMTX Sees Revenue Decline, Highlights Advances in Melanoma Thera - GuruFocus
Immatics Reports Increased Q1 2025 Loss Amid Rising R&D Costs - TipRanks
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):